Zura Bio Limited (ZURA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Zura Bio Limited (ZURA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.92

-0.03 (-1.54%)

At close: Jan 15, 2025, 10:34 AM

undefined% (undefined)

Bid	1.92
Market Cap	125.36M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.39
PE Ratio (ttm)	-4.92
Forward PE	n/a
Analyst	Buy

Ask	1.93
Volume	123,864
Avg. Volume (20D)	478,931
Open	2.00
Previous Close	1.95
Day's Range	1.92 - 2.04
52-Week Range	1.86 - 6.35
Beta	undefined

About ZURA

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 21, 2023

Employees 14

Stock Exchange NASDAQ

Ticker Symbol ZURA

Website https://zurabio.com

Analyst Forecast

According to 6 analyst ratings, the average rating for ZURA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 681.25% from the latest price.

Buy 83.33%

Hold 16.67%

Sell 0.00%

Stock Forecasts

Why Price Moved

9 months ago · Source

+17.89%

Zura Bio shares are trading higher. The company an... Unlock content with Pro Subscription

News

3 weeks ago · businesswire.com

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in adults.

1 month ago · businesswire.com

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoim...

2 months ago · businesswire.com

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoim...

2 months ago · businesswire.com

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

2 months ago · businesswire.com

Zura Bio to Participate in Two Upcoming Investor Conferences in November